DRMA vs. CNSP, NTBL, CMND, SLRX, BDRX, BPTH, QLGN, ALLR, SNOA, and CYTO
Should you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include CNS Pharmaceuticals (CNSP), Notable Labs (NTBL), Clearmind Medicine (CMND), Salarius Pharmaceuticals (SLRX), Biodexa Pharmaceuticals (BDRX), Bio-Path (BPTH), Qualigen Therapeutics (QLGN), Allarity Therapeutics (ALLR), Sonoma Pharmaceuticals (SNOA), and Altamira Therapeutics (CYTO). These companies are all part of the "pharmaceutical preparations" industry.
Dermata Therapeutics (NASDAQ:DRMA) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment, community ranking and earnings.
8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 9.4% of Dermata Therapeutics shares are owned by company insiders. Comparatively, 9.2% of CNS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, CNS Pharmaceuticals had 2 more articles in the media than Dermata Therapeutics. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 1 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 1.89 beat CNS Pharmaceuticals' score of 0.91 indicating that Dermata Therapeutics is being referred to more favorably in the media.
Dermata Therapeutics is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Dermata Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.78, meaning that its share price is 178% more volatile than the S&P 500.
Dermata Therapeutics' return on equity of -107.95% beat CNS Pharmaceuticals' return on equity.
CNS Pharmaceuticals received 42 more outperform votes than Dermata Therapeutics when rated by MarketBeat users. Likewise, 70.77% of users gave CNS Pharmaceuticals an outperform vote while only 44.44% of users gave Dermata Therapeutics an outperform vote.
Summary
Dermata Therapeutics and CNS Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.
Get Dermata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dermata Therapeutics Competitors List
Related Companies and Tools
